^

Health

Advocard

, medical expert
Last reviewed: 23.04.2024
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Advocard is a combined antianginal (anti-ischemic) drug of a group of cardiovascular drugs.

Indications Advocard

Indications for the use of this drug are:

  • cardiac ischemia;
  • all types of angina (combination therapy and relief of seizures);
  • cardiosclerosis, including after myocardial infarction;
  • myocardiopathy (myocarditis, myocardial dystrophy);
  • cardiac arrhythmia.

trusted-source[1], [2]

Release form

The form of the release is tablets of 0.01 and 0.03 grams, 10 tablets each in a blister pack.

Pharmacodynamics

Anti-ischemic, antioxidant and stabilizing cell membranes, the action of the drug Advocard is provided by the active substances included in its composition: maladen (adenosine-5-triphosphatogluconate-magnesium (II) trisodium salt), molsidomine and folic acid (vitamin B9).

Maladen contains adenosine triphosphate (ATP), magnesium and sodium salts and acts on ATP-activated (purine) receptors of chemically-dependent potassium channels. As a result, their activation and inhibition of the entry of potassium ions into the cells takes place, due to which processes are developing that contribute to the protection of the myocardium from damage associated with imbalance in supply and myocardial oxygen demand, i.e., its ischemia.

Magnesium cations suppress lipid peroxidation of cell membrane lipids, support the synthesis of ATP and intercellular interaction. Molsidomine - N-ethoxycarbonyl-3- (4-morpholinyl) sydnonimine (included in Molsidomine, Corvaton, Sidnofarm, Morial, Motazomin) - entering the body, forms an active metabolite lindidomine (SIN 1A), which promotes the release of nitric oxide, thanks to the large coronary vessels expand, the tone of the smooth muscles of their walls decreases, the aggregation of platelets decreases (that is, the risk of blood clots is reduced).

Getting into the body, folic acid (vitamin B9) is absorbed from the gastrointestinal tract and restored to tetrahydrofolic acid, which reduces the level of the sulfur-containing amino acid homocysteine, the elevated content of which in the blood plasma leads to the development of cardiovascular diseases and strokes.

trusted-source[3], [4], [5], [6], [7], [8], [9], [10], [11]

Pharmacokinetics

Pharmacokinetics of the drug, according to the official instructions, has not been studied. However, it is known that almost 90% of molsidomine after ingestion is absorbed from the digestive tract, more than 10% of the substance binds to blood plasma proteins, and its bioavailability is approximately 65%. Metabolism molsidomina passes in the liver, the excretion of metabolites is through the kidneys (with urine) and the intestines (with feces).

Folic acid is transformed in the liver and tissues, is excreted in the urine and bile.

trusted-source[12], [13], [14], [15], [16],

Dosing and administration

Method of application Advokard - sublingually (under the tongue), until the tablet is completely dissolved, regardless of food intake. Allowed resorption of the pill - for more rapid achievement of therapeutic effect.

Dosage is determined by the doctor; recommended doses - 10-90 mg Advocard 3-4 times during the day. The daily maximum dose is 400-600 mg. The standard duration of the drug is 3-4 weeks.

trusted-source[23], [24]

Use Advocard during pregnancy

Use Advocard during pregnancy and lactating women is contraindicated because of the lack of validated data regarding its safety for the fetus and infant.

Contraindications

Contraindications Adokardis are: individual hypersensitivity to the active and auxiliary substances of the drug, arterial hypotension, severe forms of bronchial asthma, cardiogenic shock, hemorrhagic stroke, craniocerebral trauma, angle-closure glaucoma, children under 14 years.

trusted-source[17], [18], [19], [20], [21]

Side effects Advocard

As a rule, the drug is well tolerated, but side effects are possible in the form of headache, falling blood pressure, tachycardia, general weakness, spasm of bronchial tubes, nausea, bitter taste in the mouth.

trusted-source[22]

Overdose

Overdose Advocard causes headache and dizziness, treatment with an overdose symptomatic.

Interactions with other drugs

Advokard increases the hypotensive effect of drugs (especially containing nitrates) to reduce blood pressure, vasodilating agents (dipyridamole, quarantil, parsedil, etc.), adrenoblockers (phentolamine, peroxan, anaprilin, etc.).

Advocard reduces the therapeutic effect of xanthinol nicotinate, aminophylline, etc. Used to improve cerebral and general blood circulation.

With the simultaneous use of the Advocard with acetylsalicylic acid, its antiplatelet effect is enhanced. Folic acid reduces the effect of drugs for the treatment of epilepsy.

trusted-source[25], [26]

Storage conditions

The drug should be stored in a dry, sheltered from sunlight, storage temperature - not above + 25 ° C.

trusted-source

Shelf life

Shelf life of the drug is 3 years.

Attention!

To simplify the perception of information, this instruction for use of the drug "Advocard" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.